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Introduction
Recent reports have found several positive effects of Vita-
min D for humans of all ages. Until recently, deficits of Vita-
min D were associated mostly with the risk of developing 
rickets [1]. Current research, however, considers reduced 
Vitamin D concentration as a potential significant risk fac-
tor for diseases such as cancer [2–4], cardiovascular disease 
[5–7], diabetes [8–10], hypertension [11–13], autoimmune 
diseases [14–16], metabolic disorders [17, 18], infectious 
diseases caused by decreased immunity [19], and some 
neuropsychiatric conditions [20]. An increasing body of 
evidence of Vitamin D’s beneficial effects prompted the 
development of nationwide recommendations to prevent 
Vitamin D deficiency in Poland (2009), Hungary (2012) and 
Germany–Austria–Switzerland (2012) [21–23]. Further-
more, the Institute of Medicine of the U.S. National Acad-
emies published ‘Dietary Reference Intakes for Calcium 
and Vitamin D’ (2010) which were extensively discussed 
by the Endocrine Society which issued its own guidelines 
(2011) [24, 25]. In 2010, the International Osteoporosis 
Foundation released a position paper on recommenda-
tions for Vitamin D nutrition in elderly men and women 
[26]. In 2012, the European Food Safety Authority released 
the revised Tolerable Upper Intake Levels (upper limits 
[ULs]) of Vitamin D for all relevant population groups [27].
Unfortunately, despite available recommendations 
on Vitamin D supplementation and its ULs, daily Vita-
28Department of Gastroenterology, Hepatology and Eating Disorders, The Children’s Memorial Health Institute, Warsaw, Poland 
29Department of Diagnostics, Jagiellonian University Medical College, Krakow, Poland 
30Department of Endocrinology and Diabetology, The Children’s Memorial Health Institute, Warsaw, Poland 
31Faculty of Health Science, UJK, Kielce, Poland 
32Semmelweis University, Faculty of Medicine, 2nd Department of Obstetrics and Gynaecology, Budapest, Hungary 
33Department of Histology, Medical University of Gdansk, Gdansk, Poland
Abstract
Introduction: Adequate Vitamin D intake and its concentration in serum are important for bone health and calcium–phosphate metabo-
lism as well as for optimal function of many organs and tissues. Documented trends in lifestyle, nutritional habits and physical activity 
appear to be associated with moderate or severe Vitamin D deficits resulting in health problems. Most epidemiological studies suggest that 
Vitamin D deficiency is prevalent among Central European populations. Concern about this problem led to the organising of a conference 
focused on overcoming Vitamin D deficiency. 
Methods: After reviewing the epidemiological evidence and relevant literature, a Polish multidisciplinary group formulated theses on 
recommendations for Vitamin D screening and supplementation in the general population. These theses were subsequently sent to Sci-
entific Committee members of the ‘Vitamin D — minimum, maximum, optimum’ conference for evaluation based on a ten-point scale. 
With 550 international attendees, the meeting ‘Vitamin D — minimum, maximum, optimum’ was held on October 19–20, 2012 in Warsaw 
(Poland). Most recent scientific evidence of both skeletal and non-skeletal effects of Vitamin D as well as the results of panellists’ voting 
were reviewed and discussed during eight plenary sessions and two workshops. 
Results: Based on many polemical discussions, including post-conference networking, the key opinion leaders established ranges of 
serum 25-hydroxyVitamin D concentration indicating Vitamin D deficiency [< 20 ng/mL (< 50 nmol/L)], suboptimal status [20–30 ng/mL 
(50–75 nmol/L)], and target concentration for optimal Vitamin D effects [30–50 ng/mL (75–125 nmol/L)]. General practical guidelines regard-
ing supplementation and updated recommendations for prophylactic Vitamin D intakes in Central European neonates, infants, children 
and adolescents as well as in adults (including recommendations for pregnant and breastfeeding women and the elderly) were developed. 
Conclusions: Improving the Vitamin D status of children, adolescents, adults and the elderly must be included in the priorities of phy-
sicians, healthcare professionals and healthcare regulating bodies. The present paper offers elaborated consensus on supplementation 
guidance and population strategies for Vitamin D in Central Europe. (Endokrynol Pol 2013; 64 (4): 319–327)
Key words: vitamin D deficiency, 25-hydroxyvitamin-D, general population guidelines, risk groups, Central Europe, supplementation
Streszczenie
Wstęp: Wyniki badań z ostatnich lat dokumentują wiele korzyści wynikających z działania witaminy D na organizm człowieka na wszystkich 
etapach jego życia. Większość badań epidemiologicznych sugeruje, że niedobór witaminy D jest powszechny wśród mieszkańców Europy 
Środkowej. Naturalną konsekwencją tej sytuacji jest konieczność ciągłego uświadamiania społeczeństwu oraz środowisku medycznemu, 
jaką rolę odgrywa witamina D w rozwoju i funkcjonowaniu organizmu ludzkiego.
Metody: Na podstawie przeglądu danych literaturowych Polski Zespół Wielodyscyplinarny opracował tezy dotyczące zasad suplemen-
tacji witaminą D, które przesłano do członków Komitetu Naukowego konferencji „Witamina D — minimum, maksimum, optimum”, 
19–20 Październik, 2012, Warszawa. W trakcie powyższej konferencji z udziałem 550 delegatów oraz Ekspertów różnych dziedzin medy-
cyny omówiono i przedyskutowano propozycje wytycznych suplementacji witaminą D populacji Europy Środkowej.
Wyniki. W efekcie przeprowadzonych dyskusji Zespół Ekspertów opracował wytyczne suplementacji witaminą D dla wszystkich grup 
wiekowych populacji Europy Środkowej. Określono również kryteria diagnostyczne charakteryzujące stan zaopatrzenia organizmu 
w witaminę D: deficyt witaminy D ustalono jako stężenie 25(OH)D < 20 ng/mL (< 50 nmol/L)], suboptymalne zaopatrzenie jako stężenie 
25(OH)D wynoszące 20–30 ng/mL (50–75 nmol/L), a stężenie 30–50 ng/mL (75–125 nmol/L) uznano za docelowe dla zapewnienia efektu 
plejotropowego witaminy D.
Wnioski. Poprawa obecnego stanu zaopatrzenia witaminy D w grupach dzieci, młodzieży, osób aktywnych zawodowo i seniorów 
powinna zostać włączona do priorytetów polityki zdrowotnej społeczeństw Europy Środkowej. (Endokrynol Pol 2013; 64 (4): 319–327)
Słowa kluczowe: niedobór witaminy D, 25-hydroksywitamina D, wytyczne populacyjne, grupy ryzyka, suplementacja 
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min D intake is rigorously preserved only during the 
first months of life; later in life, Vitamin D is given only 
occasionally, if at all. The evident consequence is low 
average Vitamin D concentration among populations 
of Central Europe, indicating a need for continuous 
awareness by the public and the medical community. 
Adequate Vitamin D status is associated with the overall 
health of infants, children, adolescents, professionally 
active people and the elderly. By contrast, inadequate 
Vitamin D concentration (even if considered an epi-
phenomenon) is frequently noted in patients suffering 
from a wide spectrum of diseases [1–20].
The Vitamin D doses recommended here are based 
on both well-documented skeletal effects and an in-
creasing number of well-designed studies suggesting 
extra-skeletal effects. These recommendations apply not 
only in the context of preventing rickets or osteoporosis, 
but also in a broader context of preventive action against 
many disorders and morbidities that affect people of all 
ages. The main goal of proper Vitamin D supplementa-
tion is to ensure an adequate serum 25-hydroxyVitamin 
D [25(OH)D] concentration and, thereby, to guarantee 
short- and long-term effects, with appropriate safety 
considerations. 
Sources of Vitamin D
Adequate Vitamin D intake, positive calcium balance 
and outdoor physical activity i.e. weight-bearing 
exercise are essential for appropriate skeletal growth 
and bone mineralisation. These environmental factors 
also show a liability to reduce risk of several diseases. 
A diverse diet rich in food containing large amounts 
of Vitamin D, including oily fish, is important (Table 
I). If the additive effect of dietary Vitamin D con-
sumption and sunlight-induced Vitamin D synthesis 
in the skin is insufficient, taking supplements be-
comes essential to achieve optimal Vitamin D status. 
Because the circulating metabolite of Vitamin D has 
a long serum half-life (4–6 weeks) and is stored in 
tissues, Vitamin D can be administered other than 
once per day — for example, every other day, twice 
per week, or once weekly. This flexibility answers 
the technical problems of dividing drops and the 
higher-than-required dose of available commercial 
preparations. 
Most Vitamin D in the human body is produced in 
the skin after exposure to sunlight, specifically solar 
ultraviolet-B irradiance. Sunscreens, which are widely 
used in Europe during the summer, may reduce skin 
synthesis by 90–95% [28]. In Central Europe, solar 
angle and weather conditions suitable for Vitamin 
D synthesis occur between late April and early Sep-
tember; whereas skin synthesis does not occur from 
October to March [29]. The efficacy of skin synthesis 
basically depends on two factors: the degree of skin 
pigmentation and age. For optimal effect, Central 
Europeans should expose, without sunscreen, 18% of 
the body surface (i.e. uncovered forearms and partially 
exposed legs) to a half of one minimal erythemal dose 
(MED, defined as slight reddening of skin 24 h post 
exposure) two or three times per week. In practical 
terms, exposing 18% of the body to the sun without 
sunscreen for approximately 15 minutes a day be-
tween 10 a.m. and 3 p.m. is likely to be adequate for 
fair-skinned Central Europeans. The advantages and 
disadvantages of sun exposure must be balanced, at 
least during summer, because excessive sun exposure 
is a potential risk factor for skin cancer [30]. Direct 
exposure to the sun is not recommended for infants 
younger than six months. Experiencing many severe 
sunburns up to young adulthood is considered a se-
rious risk factor for skin cancer. Sun exposure is not 
recommended for people with skin type 1 (pale white 
Table I. Sources of vitamin D 
Tabela I. Źródła witaminy D
Source Vitamin d content
Cod liver oil ~400–1,000 IU/tsp
Eel, fresh ~1,200 IU/100 g
Salmon, fresh wild caught ~600–1,000 IU/100 g
Herring in oil ~800 IU/100 g
Pickled herring ~480 IU/100 g
Salmon, fresh farmed ~100–250 IU/100 g
Salmon, tinned ~300–600 IU/100 g
Sardines, tinned ~300 IU/100 g
Mackerel, tinned ~250 IU/100 g
Tuna, tinned ~230 IU/100 g
Shiitake mushrooms, fresh ~100 IU/100 g
Egg yolk ~20–50 IU/yolk
Cheese ~7–28 IU/ 100 g
Breast milk ~1.5–8 IU/100 mL
Cow’s milk ~0.4–1.2 IU/100 mL
Milk-corny gruels ~60–80 IU/100 mL
Infant formula (beginning formula) ~40–50 IU/100 mL
Infant formula (follow-up formula) ~40–80 IU/100 mL
Formula for children aged 12 months 
or older
~70–80 IU/100 mL
Skin synthesis/UVB radiation Exposure of arms and legs to 
0.25–0.50 minimal erythemal 
dose (MED) is estimated 
equivalent of ~2,000–4,000 IU 
Vitamin D3.
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skin, blue eyes, red hair) or with a history of sunburns 
or a history of skin cancer in the family.
Recommended Vitamin D intakes in the 
general population
1. Neonates and infants (0–12 months):
 — vitamin D supplementation should be introduced 
from the first days of life, irrespective of nutritional 
option (breastfeeding or/and formula-based nutrition);
 — supplementation of 400 IU/day (10.0 µg/day) up to 
age 6 months;
 — supplementation of 400–600 IU/day (10.0–15.0 µg/
day) between 6 and 12 months of age depending 
on daily Vitamin D intake from diet. 
2. Children and adolescents (1–18 years):
 — supplementation of 600–1,000 IU/day (15.0–25.0 µg/
day), depending on body weight, is recommended 
between September and April;
 — supplementation of 600–1,000 IU/day (15.0–25.0 µg/
day), depending on body weight, is recommended 
throughout the whole year, if sufficient skin syn-
thesis of Vitamin D is not ensured in the summer. 
3. Adults (> 18 years) and the elderly:
 — supplementation of 800–2,000 IU/day (20.0–50.0 µg/
day), depending on body weight, is recommended 
between September and April;
 — supplementation of 800–2,000 IU/day (20.0–50.0 µg/
day), depending on body weight, is recommended 
throughout the whole year, if sufficient skin syn-
thesis of Vitamin D is not ensured in the summer;
 — the elderly (65 years and above) should be supple-
mented with 800–2,000 IU/day (20.0–50.0 µg/day) 
throughout the whole year, because of the reduced 
efficacy of Vitamin D skin synthesis.
4. Pregnant and breastfeeding women:
 — women who plan pregnancy should start/maintain 
Vitamin D supplementation as recommended for 
adults. Adequate Vitamin D intake before pregnancy 
should be ensured;
 — vitamin D supplementation of 1,500–2,000 IU/day 
(37.5–50.0 µg/day) should begin at least from the 
second trimester of pregnancy. Gynaecologists/ 
/obstetricians should consider starting Vitamin D 
supplementation for pregnant women soon after 
pregnancy is confirmed;
 — if feasible, periodical monitoring of serum 25(OH)D 
concentration should be done to define optimum dos-
age and to verify efficacy of supplementation. The goal 
of supplementation is to achieve and maintain 25(OH)
D concentration of 30–50 ng/mL (75–125 nmol/L).
Recommended Vitamin D intakes in 
groups at risk of Vitamin D deficiency
1. Premature infants:
 — vitamin D supplementation should be introduced 
from the first days of life (as soon as enteral feeding 
is possible);
 — supplementation of 400–800 IU/day (10–20 µg/day) 
until accomplishing the corrected gestational age of 
40 weeks should be warranted; thereafter, the recom-
mendations as for normal-term infants are adequate.
2. Obese children and adolescents (BMI > 90th 
percentile for age and gender using local reference 
in a given country):
 — Supplementation of 1,200–2,000 IU/day (30–50 µg/ 
/day), depending on severity of obesity, is recom-
mended between September and April.
 — Supplementation of 1,200–2,000 IU/day (30–50 µg/ 
/day), depending on severity of obesity, is recom-
mended throughout the whole year, if sufficient skin 
synthesis of Vitamin D is not ensured in the summer. 
3. Obese adults and the elderly (BMI 30+ kg/m2):
 — supplementation of 1,600–4,000 IU/day (40–100 µg/
day), depending on severity of obesity, is recom-
mended throughout the whole year;
 — sensible exposure to sunlight in the context of ad-
ditional oral Vitamin D intake is safe.
4. Night workers and dark-skinned adults:
 — supplementation of 1,000–2,000 IU/day (25–50 µg/ 
/day), depending on body weight, is recommended 
throughout the whole year for dark-skinned persons;
 — supplementation of 1,000–2,000 IU/day (25–50 µg/ 
/day), depending on body weight, is recommended 
for night workers throughout the whole year.
Recommended tolerable UL values for 
Vitamin D intake in the general population
The tolerable UL value is the highest average daily Vita-
min D oral intake likely to pose no risk of adverse effects 
for Central European populations during growth and 
maturation, adulthood and ageing. The UL for Vitamin 
D does matter in healthy individuals, whereas at least 
two diseases should be considered as exceptions from 
the general rule, i.e.: 
 — Granulomatous conditions (e.g. sarcoidosis), with 
excessive extrarenal 1-a-hydroxylase (CYP27B1) 
expression, excessive uncontrolled 1,25-dihy-
droxyVitamin D (calcitriol) production causing 
hypercalcemia at relatively low serum 25(OH)D 
concentration [33]; in granulomatous conditions, the 
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recommended target for serum 25(OH)D concentra-
tion is approximately 25 ng/mL (62.5 nmol/L) [31].
 — Genetic absence of, or defective, 24-hydroxylase 
(CYP24A1) activity (as in idiopathic infantile hy-
percalcemia, which can remain unnoticed until 
adulthood and cause nephrolithiasis in later 
life), a situation that compromises the ability of 
the kidneys or target cells to destroy 25-hydroxy-
Vitamin D or calcitriol, leading to hypercalciuria 
and/or hypercalcemia at relatively ‘normal’ 25(OH)D 
concentrations [32]
The Panel of Experts adopted the European Food 
Safety Authority scientific opinion on the Tolerable 
Upper Intake Levels of Vitamin D for all relevant 
population groups, except obese adults and the 
elderly [27]. The highest average daily Vitamin D 
intakes likely to pose no risk of adverse effects are 
as follows:
 — For neonates and infants, 1,000 IU/day (25 µg/day);
 — For children aged 1–10 years, 2,000 IU/day (50 µg/ 
/day)
 — For children and adolescents aged 11–18 years, 4,000 
IU/day (100 µg/day);
 — For adults and the elderly with normal body weight, 
4,000 IU/day (100 µg/day);
 — For obese adults and obese elderly people, 10,000 
IU/day (250 µg/day);
 — For both pregnant and breastfeeding women, 4,000 
IU/day (100 µg/day).
Recommended therapeutic doses for 
patients with verified Vitamin D deficiency
Assessment of Vitamin D status and diagnostic 
criteria
The serum concentration of 25(OH)D — the main 
measurable circulating Vitamin D metabolite — indi-
cates Vitamin D status. Total 25(OH)D concentration 
reflects delivery of Vitamin D from both cutaneous 
and oral sources. The 25(OH)D serum concentration is 
expressed in nanograms per millilitre or nanomoles per 
litre (1 ng/mL = 2.5 nmol/L). Recent analytical methods 
are, in general, applied by fully automated platforms 
used in routine clinical chemistry laboratories. For routine/ 
/clinical 25(OH)D testing, we recommend methods that 
measure both 25(OH)D2 and 25(OH)D3, giving a total 
25(OH)D serum concentration value, with an intra-assay 
coefficient of variation of less than 5% and an interassay 
coefficient of variation of less than 10%. The best assays 
provide total 25(OH)D concentration, excluding a recently 
discovered metabolite, 3-epi-25(OH)D3 [33, 34].
The diagnostics thresholds defining concentrations 
of serum 25(OH)D approved in Central Europe are as 
follows:
 — concentrations below 20 ng/mL (50 nmol/L) indi-
cate Vitamin D deficiency, which should be treated 
medically;
 — concentrations of 20 ng/mL (50 nmol/L) up to 
30 ng/mL (75 nmol/L) reflect a suboptimal Vitamin D 
status that calls for a moderate increase of Vitamin 
D daily dose;
 — concentrations higher than 30 ng/mL (75 nmol/L) up 
to 50 ng/mL (125 nmol/L) reflect adequate Vitamin 
D status; the supplementation scheme and dose 
should be maintained;
 — concentrations higher than 50 ng/mL (125 nmol/L) 
up to 100 ng/mL (250 nmol/L) indicate a high 
Vitamin D supply; the supplementation dose 
can be maintained for lower concentrations of 
this range or moderately decreased for higher 
concentrations;
 — concentrations higher than 100 ng/mL (250 nmol/L) 
are risky for overall health outcomes and need 
reduction/cessation of Vitamin D supplementation 
until obtaining target 25(OH)D concentration;
 — concentrations higher than 200 ng/mL (500 
nmol/L) are considered toxic and require cessation 
of Vitamin D supplementation until obtaining 
target 25(OH)D concentration; such people may 
need specific medical intervention to correct toxic 
effects.
Indications for 25(OH)D testing
There are various clinical circumstances and condi-
tions, involving all age groups, in which serum 25(OH)
D measurements are justified. Vitamin D deficiency 
accompanies e.g. renal or liver malfunctions, malab-
sorption, maldigestion syndromes and obesity, and it 
can coexist with various treatments (e.g. with anticon-
vulsants, glucocorticoids, ketoconazole). Untreated 
Vitamin D deficiency can significantly reduce the ef-
fectiveness of such underlying therapy or modify the 
course of a disease. 
We recommend 25(OH)D testing in:
 — patients with rickets, osteomalacia, musculoskeletal 
pain, propensity to falls, idiopathic and secondary 
osteoporosis including patients with osteoporotic 
fractures, and history of low-energy fractures of 
different origin;
 — patients with calcium/phosphate metabolism ab-
normalities;
 — patients with hyperparathyroidism;
 — patients with prolonged glucocorticoid therapy at 
the dose of 7 mg of prednisone per day or higher;
 — patients taking anticonvulsant medications;
 — patients taking ketoconazole;
 — patients taking anti-AIDS medications (antiretroviral 
therapy);
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 — patients with malabsorption syndromes (coeliac 
disease, Crohn’s disease, past gastrointestinal by-
pass surgery, cystic fibrosis, inflammatory bowel 
disease);
 — patients treated with long-lasting elimination diets 
implemented for the management of cow’s milk 
allergy, lactose intolerance/hypolactasia; total par-
enteral nutrition; eating disorders;
 — patients with chronic kidney disease stage 3–5 and 
kidney transplant recipients
 — patients with hepatic failure and/or cholestasis;
 — patients with granulomatous disorders (tuberculo-
sis, sarcoidosis);
 — patients with different types of cancer;
 — patients with cardiovascular diseases, especially 
hypertension;
 — patients with some chronic autoimmune diseases 
(multiple sclerosis, psoriasis, rheumatoid arthritis, 
dermatomyositis, lupus/SLE);
 — patients admitted to hospital because of some infec-
tions (hepatitis C, recurrent acute lower respiratory 
tract infection) and chronic allergic diseases such as 
atopic dermatitis or atopic asthma.
Treatment 
Individuals with diagnosed Vitamin D deficiency 
require higher doses of Vitamin D than those recom-
mended for the general population. The therapeutic 
dose in severe depletion should be 1,000–10,000 IU/ 
/day (~50,000 IU/week), depending on the patient’s 
age and body weight. Loading doses of 300,000 IU 
and higher are not recommended, even for the 
treatment of severe deficiency [35]. The duration of 
supplementation usually varies from 1–3 months, 
depending on the severity of Vitamin D deficiency. 
After a patient achieves the 25(OH)D concentration 
of 30–50 ng/mL (75–125 nmol/L), a maintenance 
dose may be instituted. It is reasonable to reevaluate 
25(OH)D concentration after 3–4 months and then 
to monitor semi-annually, especially with the coin-
cidence of exacerbating factors such as obesity that 
need therapeutic doses covering the upper range 
of standard dosage. In cases with severe deficits, 
monitoring of serum calcium and phosphate con-
centrations, total alkaline phosphatase (ALP) activity 
and calciuria rate in spot urine (Ca/CR ratio) may 
be desirable.
Analogues such as 1a-(OH)D3, 1a,25(OH)2D3, 
19-nor-1a 25(OH)2D2, 1a-(OH)D2, 22-oxa-1a,25(OH)2D3, 
22-oxa-1a,25(OH)2D3, and others should not be used to 
manage Vitamin D deficiency. Analogues may be ap-
plied in disorders of Vitamin D hydroxylation associated 
with chronic renal disease. 
Recommended therapeutic doses of Vitamin D 
(treatment duration lasting 1–3 months):
 — for neonates (i.e. younger than one month) with 
25(OH)D concentration lower than 20 ng/mL (50 
nmol/L), 1,000 IU/day (25 µg/day)
 — for infants aged 1–12 months with 25(OH)D 
concentration lower than 20 ng/mL (50 nmol/L), 
1,000–3,000 IU/day (25–75 µg/day), depending on 
body weight
 — for children and adolescents aged 1–18 years with 
25(OH)D concentration lower than 20 ng/mL (50 
nmol/L), 3,000-5,000 IU/day (75–125 µg/day), de-
pending on body weight
 — for adults and the elderly with 25(OH)D concentra-
tion lower than 20 ng/mL (50 nmol/L), 7,000–10,000 
IU/day (175–250 µg/day), depending on body 
weight, or 50,000 IU/week (1250 µg/week)
The algorithm summarises current recommenda-
tions.
Discussion
Recommendations for serum 25(OH)D concentrations 
and Vitamin D supplementation are based on studies of 
health outcomes with respect to either serum 25(OH)D 
concentrations or Vitamin D intakes. Three types of obser-
vational studies deal with the analysis of health outcomes 
with respect to serum 25(OH)D concentrations:
 — case-control studies that use serum 25(OH)D con-
centrations measured at the time of health outcome 
diagnosis;
 — cohort studies that use serum 25(OH)D concentra-
tions measured at the time of enrollment, with 
health outcome determined after several years of 
follow-up;
 — cross-sectional studies that sample the population 
and examine correlations between serum 25(OH)D 
concentrations and health conditions
All three types of study are useful, but each has 
inconsistencies and different levels of evidence. The 
health condition in question may influence serum 
25(OH)D concentration at the time of diagnosis. How-
ever, this possibility seems unlikely for health outcomes 
that are not known until diagnosed, such as cancer 
incidence, since there is a smooth, continuous change 
in cancer incidence rates with respect to follow-up time 
[36]. Serum 25(OH)D concentration at the time of enroll-
ment in cohort studies may not be the concentration 
relevant to reducing risk of the health outcome. In ad-
dition, as serum 25(OH)D concentrations change over 
time, the longer the follow-up period, the lower the 
beneficial effect that is found [36, 37]. In cross-sectional 
studies, a health condition may considerably influence 
serum 25(OH)D concentration, for example for those 
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staying indoors due to an illness. Despite several limita-
tions of these studies, they form the primary basis of our 
understanding of the benefits of Vitamin D for many 
health outcomes. The results of such studies become 
more reliable in the context of meta-analyses, which 
combine all similar using a weighting scheme based 
on the number of cases in each study.
In addition, ecological studies based on geographic 
or seasonal variations are meaningful, especially in 
generating hypotheses, because solar ultraviolet-B is 
the primary source of Vitamin D for 90% of the popu-
lation. Examples include geographical variation for 
many types of cancer [38, 39] and seasonal variation 
in cancer incidence [40]. A study on cancer incidence 
with respect to occupation in Nordic countries provides 
well-balanced evidence that solar UVB reduces risk of 
many types of cancer [41]. No mechanism other than 
Vitamin D production has been proposed to explain 
the findings from ecological studies of cancer incidence 
and/or mortality rates with respect to solar UVB doses 
across countries. Furthermore, there is much additional 
support elsewhere for the role of Vitamin D in reducing 
the risk of cancer [3, 4].
Researchers conduct randomised controlled trials 
(RCTs) to overcome the problems of observational 
studies. RCTs, however, also demonstrate several meth-
odological issues. 
According to Lappe and Heaney [42], a well-con-
ducted RCT should:
 — start with a general idea of the relation between 
serum 25(OH)D concentration and health outcome;
 — enroll people near the low end of 25(OH)D con-
centration;
 — give those in the treatment arm enough Vitamin D to 
increase serum 25(OH)D concentration to the point 
that little additional benefit is expected;
 — measure serum 25(OH)D concentration both at time 
of enrollment and after supplementation.
Table II. Evidence of associations between serum 25(OH)D concentrations above 30 ng/mL and optimal health
Tabela II. Przykłady badań dokumentujących związek między stężeniem 25(OH)D powyżej 30 ng/ml a optymalizacją stanu 
zdrowia
Health outcome Study type/design 25(OH)D concentrations studied Finding Reference
Breast cancer 
incidence
Meta-analysis of five case-
control studies of breast cancer 
incidence
30 ng/mL vs. 10 ng/mL OR = 0.44 Grant [46]
Colorectal cancer 
incidence
Meta-analysis of ten case-control 
and cohort studies of colorectal 
cancer incidence
30 ng/mL vs. 5 ng/mL OR = 0.40 Grant [4]
CVD Prospective study with mean 
follow-up time of 1.3 years
30 ng/mL vs. < 15 ng/mL Adjusted HR = 1.62 (95% CI, 
1.38–1.89)
Anderson et al. [5]
CVD Random-effects meta-analysis of 
nine prospective studies with  
< 10 years of follow-up
Lowest vs. highest Pooled relative risk = 1.86 
(95% CI, 1.47–2.34) for 
incident CVD
Wang et al. [6]
Type 2 diabetes 
mellitus
Meta-analysis of seven 
prospective studies
> 25 ng/mL vs. <14 ng/mL RR = 0.57 (95% CI, 
0.43–0.76)
Mitri et al. [8]
Type 2 diabetes 
mellitus, 
Prospective observational 
study with a mean follow-up 
of 2.7 years in patients with 
prediabetes
30.1 ng/mL vs. 12.8 ng/mL HR = 0.72 (95% CI, 
0.56–0.90)
Pittas et al. [10]
Cognitive 
impairment
Elderly women older than 70 
years
< 10 ng/mL vs. >30 ng/mL OR = 1.60 (95% CI, 
1.05–2.42)
Slinin et al. [47]
Cognitive decline Elderly women older than 70 
years; cognitive decline 2–4 
years after baseline
< 10 ng/mL vs. >30 ng/mL OR = 1.58 (95% CI, 1.12–
2.22) for > 1-σ cognitive 
decline from mean
Slinin et al. [47] 
Hip fracture Pooled analysis of RCTs Highest Vitamin D intake  
(median, 800 IU daily; range, 
792–2,000) vs. lowest
HR = 0.70 (95% CI, 
0.58–0.86)
Bischoff-Ferrari et 
al. [43]
Mortality,  
all-cause
Meta-analysis of 11 prospective 
studies
Minimum RR near 30–35 ng/mL 
25(OH)D vs. lowest 25(OH)D
Relative risk = 0.71 (95% CI, 
0.50–0.91)
Zittermann et al. [48]
Respiratory infections, 
acute viral
Infections in autumn/winter > 38 ng/mL vs. <38 ng/mL RR = 0.51 (95% CI, 
0.25–0.84)
Sabetta et al. [49]
CI — confidence interval; CVD — cardiovascular disease; HR — hazard ratio; OR — odds ratio; RR — risk ratio
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Furthermore, as many other sources of Vitamin D 
exist, studies have to control them all. Unfortunately, 
most RCTs conducted to date have not followed these 
guidelines. Several investigations have considered a 
daily Vitamin D dose of only 400 IU, which confers 
little health benefit. Nonetheless, a few studies have 
confirmed some of the findings from observational 
studies, such as for fractures [43], all-cancer incidence 
[44], and type A influenza [45], however, this was not 
consistently shown in all RCTs either. 
While RCTs would provide an extra level of confi-
dence to the Vitamin D recommendations, it seems that 
there is sufficient evidence of the beneficial effects of 
Vitamin D intake and/or production with very limited 
adverse effects that the general health of the popula-
tion would be significantly improved by adopting the 
recommendations proposed in this paper. 
Table II presents an overview of findings from the 
journal literature regarding health outcomes as a func-
tion of serum 25(OH)D concentration or oral Vitamin 
D intake. The examples chosen were generally derived 
from recently published papers, with an emphasis on 
meta-analyses. 
Conclusions
There is an urgent need to improve the Vitamin D status 
of children, adolescents, adults and the elderly. The pre-
sent paper offers elaborated consensus on supplementa-
tion guidance and population strategies for Vitamin D 
in Central Europe. Prophylaxis of Vitamin D deficiency 
should be included in the priorities of physicians, medical 
professionals and healthcare policy-makers. 
It is postulated to adopt our practical guidelines on 
vitamin D supplementation to population of Central 
Europeans 
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